Induction of tumor immunity by variants of folate binding protein
AssigneesBoard of Regents, The University of Texas System, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsConstantin G. IOANNIDES, George E. PEOPLES
Life of this patent
Estimating the term…
Abstract
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.
Claims29
1-22. (canceled)
A method of inducing immunity against a cancer expressing folate binding protein (SEQ ID NO:10) in an individual, the method comprising administering to the individual an effective amount a first vaccine composition comprising a peptide consisting of the amino acid sequence EIWTFSTKV (SEQ ID NO:
- 5).
A method of inducing immunity against a cancer expressing folate binding protein (SEQ ID NO:10) in an individual, the method comprising administering to the individual an effective amount a first vaccine composition comprising a peptide consisting of the amino acid sequence EIWTFSTKV (SEQ ID NO:
- 5), and subsequently administering an effective amount of a second vaccine composition comprising a peptide consisting of the amino acid sequence EIWTHSYKV (SEQ ID NO:
- 268).
A method of inducing immunity against a cancer expressing folate binding protein (SEQ ID NO:10) in an individual, the method comprising administering to the individual an effective amount a first vaccine composition comprising a peptide consisting of the amino acid sequence EIWTHSYKV (SEQ ID NO:
- 268), and subsequently administering an effective amount of a second vaccine composition comprising a peptide consisting of the amino acid sequence EIWTFSTKV (SEQ ID NO:
- 5).
Dependencies are inferred from the claim text.